In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to EAPC Ivory (& above) Members, Fellows of the ESC and Young combined Members

Smoking cessation rates in coronary patients across Europe: results from the EuroAspire IV survey

Session Poster Session III - Saturday 08:30 - 12:30

Speaker Marjolein Snaterse-Zuidam

Congress : EuroPrevent 2017

  • Topic : preventive cardiology
  • Sub-topic : Tobacco
  • Session type : Poster Session
  • FP Number : 770

Authors : M Snaterse-Zuidam (Amsterdam,NL), HT Jorstad (Amsterdam,NL), JW Deckers (Rotterdam,NL), D De Bacquer (Ghent,BE), RJG Peters (Amsterdam,NL), C Jennings (London,GB), K Kotseva (London,GB), WJM Scholte Op Reimer (Amsterdam,NL)

Authors:
M Snaterse-Zuidam1 , HT Jorstad2 , JW Deckers3 , D De Bacquer4 , RJG Peters2 , C Jennings5 , K Kotseva5 , WJM Scholte Op Reimer1 , 1Amsterdam University of Applied Sciences, School of Nursing/Academic Medical Center - Amsterdam - Netherlands , 2Academic Medical Center, University of Amsterdam, Department of Cardiology - Amsterdam - Netherlands , 3Erasmus Medical Center, Department of Cardiology - Rotterdam - Netherlands , 4Ghent University, Public Health - Ghent - Belgium , 5Imperial College London, Faculty of Medicine - London - United Kingdom ,

On behalf: EUROASPIRE Investigators

Citation:
European Journal of Preventive Cardiology ( April 2017 ) 24 ( Supplement 1 ), 171

Background: An (acute) coronary event offers an important window of opportunity for smoking cessation in patients with cardiovascular disease (CVD). Objective We investigated differences in pre- event smoking rates and later smoking cessation rates in patients with CHD across Europe.
Methods: We performed our analyses on 7998 patients from the EUROASPIRE IV survey (in 24 European countries) admitted for myocardial infarction, unstable angina and/or coronary revascularization procedure. Patients were interviewed in the period between 6 months and 3 years following their index event. Smoking status was objectively verified by a smoker analyser (measuring carbon monoxide in exhaled air). For each country we calculated the quit ratio and pre-index event smoking ratio. We stratified the 24 countries using two cut-offs: 1) pre-index event smoking ratio 0.30 (mean prevalence) and 2) quit rate ratio 0.50 (mean quit ratio).
Results: We observed four groups on the basis of the association between the ratio of pre-index event smokers and quit rates after the event (Figure): 1) four countries had a high prevalence of smoking before the index event (>30%) with a high quit rate (>0.50) after the index event; 2) eight countries had a high pre-index event prevalence (>30%) and low quit rate (<0.50); (3) four countries had a low pre-index event prevalence (<30%) and high quit rate (>0.50); 4) seven countries had a low pre-index event prevalence (<30%) and low quit rate (<0.50). Of selected characteristics we only found a difference for the characteristics 'no history of CVD' and 'smoking prevalence in the population' between countries with high and low pre-index smoking prevalence. (Table) Conclusion Our study shows wide variation in cessation rates in a large contemporary European survey. Smoking cessation rates in patients with a CHD event should be interpreted in the light of pre-index smoking prevalences and caution is advised when just comparing cessation rates across Europe. Our findings may assist in developing strategies to help patients with CHD to quit smoking, particularly countries with high prevalence and low quit rate.

pre-index event smoking (%) smoking population (2013) (%) age at event (years, sd) higher education (%) no history of CVD (%) obesity >=30kg/m2 (%)
High pre-index prevalence, high quit rate 42 33 56 (8.9) 20 64 37
High pre-index prevalence, low quit rate 38 30 56 (9.2) 20 60 42
Low pre-index prevalence, high quit rate 24 29 57 (9.6) 23 44 47
Low pre-index prevalence, low quit rate 25 24 58 (9.5) 21 48 41
Higher education: college, university. Smoking population: WHO database (2013).


Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are